Aspen Park Pharmaceuticals, Inc., a New York City-based therapeutics company, raised a Series A funding of undisclosed amount.
A select group of New York based backers made the investment.
The company intends to use the funds for the late stage clinical development of a patented, proprietary novel formulation of clomiphene citrate for restoring the body’s ability to make its own testosterone in men with secondary hypogonadism, and for the marketing of a fully developed product, PREBOOST™ OTC, for the prevention of premature ejaculation.
Co-founded in 2014 by two board certified urologists, Harry Fisch, M.D. and Mitchell Steiner, M.D., Aspen Park Pharmaceuticals focuses on the development and commercialization of novel therapies for men’s health diseases and conditions, including male secondary hypogonadism, prostate cancer, and sexual dysfunction.
The company is currently in litigation with Repros Therapeutics, Inc. (RPRX) to include Dr. Harry Fisch as a coinventor on patents for the use of a formulation of clomiphene called Androxal® to treat testosterone deficiency and related symptoms. The NDA for Androxal® is expected to be filed in early 2015.
The litigation trial is scheduled for February 2015.